Archontogeorgis Konstantinos, Nena Evangelia, Papanas Nikolaos, Steiropoulos Paschalis
Department of Pneumonology, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Laboratory of Hygiene and Environmental Protection, Medical School, Democritus University of Thrace, 68100 Alexandroupolis, Greece.
Pulm Med. 2014;2014:930535. doi: 10.1155/2014/930535. Epub 2014 Nov 27.
Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent episodes of upper airway collapse associated with oxygen desaturation and sleep disruption. It is proposed that these periodic changes lead to molecular variations that can be detected by assessing serum biomarkers. Studies have identified inflammatory, oxidative, and metabolic perturbations attributable to sleep-disordered breathing. Given that OSAS is associated with increased cardiovascular and cerebrovascular morbidity, the ideal biomarker should enable timely recognition with the possibility of intervention. There is accumulating data on the utility of serum biomarkers for the evaluation of disease severity, prognosis, and response to treatment. However, current knowledge is limited by data collection techniques, disease complexity, and potential confounding factors. The current paper reviews the literature on the use of serum biomarkers in OSAS. It is concluded that the ideal serum biomarker still needs to be discovered, while caution is needed in the interpretation of hitherto available results.
阻塞性睡眠呼吸暂停综合征（OSAS）的特征是上气道反复塌陷，并伴有氧饱和度下降和睡眠中断。有人提出，这些周期性变化会导致分子变异，可通过评估血清生物标志物来检测。研究已经确定了睡眠呼吸紊乱所致的炎症、氧化和代谢紊乱。鉴于OSAS与心血管和脑血管发病率增加有关，理想的生物标志物应能实现及时识别并有可能进行干预。关于血清生物标志物在评估疾病严重程度、预后及治疗反应方面的效用，已有越来越多的数据。然而，目前的认知受到数据收集技术、疾病复杂性和潜在混杂因素的限制。本文综述了关于血清生物标志物在OSAS中应用的文献。结论是，仍需发现理想的血清生物标志物，同时在解释迄今可得的结果时需谨慎。
